McDermott advises syndicate of Amolyt Pharma’s historical investors in €67.6 million Series B financing

Overview


PARIS (September 17, 2021) – McDermott Will & Emery advised a syndicate of Amolyt Pharma’s historical investors, including LSP, Novo and Kurma Partners, in a €67.6 million Series B financing led by Sectoral Asset Management and Andera Partners.

Amolyt Pharma is a global company specialized in developing therapeutic peptides for rare endocrine and related diseases.

The funds raised will be invested in the clinical development of AZP-3601 for the treatment of hypoparathyroidism, the preclinical development of AZP-3813 in acromegaly and ongoing research related to AZP-3404. In addition, the company continues to work to further expand its early-stage pipeline through both internal research and development activities and potential inlicensing opportunities.

The McDermott team that advised the existing investors comprised:

  • Anthony Paronneau, partner, and Tess Souquet-Basiege, associate